“Growing Adoption of Molecular Diagnostics and Immunoassays for Quicker Disease Detection”
The point of care (POC) clinical chemistry and immunodiagnostic market is rapidly expanding, driven by technological advancements in diagnostic tools and the increasing demand for real-time, on-site testing. One prominent trend in this market is the growing adoption of molecular diagnostics and immunoassays for quicker disease detection. These tests are revolutionizing the healthcare landscape, providing fast, accurate results for conditions such as infectious diseases, diabetes, and cardiovascular issues. For instance, Abbott’s ID NOW platform, which provides rapid molecular testing for COVID-19, has gained significant traction due to its efficiency in delivering results in under 15 minutes. The convenience of these compact, portable devices has made them indispensable in hospitals, clinics, and even home care settings. In addition, the rise of telehealth and remote patient monitoring is accelerating the demand for POC testing, as it enables healthcare providers to make timely decisions without requiring patients to visit healthcare facilities. This trend is expected to drive continued growth in the POC clinical chemistry and immunodiagnostic market.
